Pakistan’s Ferozsons to manufacture US-based Gilead's HIV prevention drug
Ferozsons Laboratories Limited (FEROZ), a Pakistani pharmaceutical company, has joined a select group of global manufacturers in Gilead Sciences’ expanded royalty-free licensing programme for its investigational once-yearly lenacapavir for HIV prevention, covering 120 high-incidence countries. The listed pharma disclosed the development in a notice to the Pakistan Stock Exchange (PSX) on…
Pakistani pharmaceutical company Ferozsons Laboratories Limited (FEROZ) has entered into an expanded royalty-free licensing agreement with US-based Gilead Sciences for the production of their investigational HIV prevention drug, lenacapavir. The agreement covers 120 high-incidence countries, primarily low- and lower-middle income nations.
This move will support manufacturing readiness, technology transfer, and future supply planning during the ongoing Phase 3 PURPOSE 365 trial. If the once-yearly lenacapavir is approved, it could offer a full year of HIV prevention with a single dose, expanding prevention options and addressing barriers to pre-exposure prophylaxis (PrEP) uptake and persistence.
Ferozsons will manufacture the injectable drug at its JV subsidiary, BF Biosciences Limited, while selling the oral variant directly.
Written by urgent.news from Business Recorder's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
